Zimmer Biomet (NYSE:ZBH) Price Target Raised to $100.00

Key Points

• Canaccord Genuity raised Zimmer Biomet’s price target from $83 to $100 while maintaining a “hold” rating, implying approximately 3.59% upside. Analysts overall also rate the stock “Hold,” with an average target of $104.42.
• Zimmer Biomet reported quarterly EPS of $2.07, beating estimates by $0.06, while revenue reached $2.18 billion and increased 4.8% year over year. The company guided to fiscal 2026 EPS of $8.47–$8.59.
• The stock opened at $96.54, with a market capitalization of $18.41 billion and a 52-week range of $79.12 to $108.29. An insider recently sold 5,000 shares, while institutional investors own 88.89% of the company.

Zimmer Biomet (NYSE:ZBH - Get Free Report) had its target price raised by equities research analysts at Canaccord Genuity Group from $83.00 to $100.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a "hold" rating on the medical equipment provider's stock. Canaccord Genuity Group's price objective would indicate a potential upside of 3.59% from the stock's current price.

A number of other equities analysts have also recently issued reports on the stock. Wells Fargo & Company decreased their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 29th. Weiss Ratings upgraded shares of Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. reduced their price target on Zimmer Biomet from $100.00 to $95.00 and set a "neutral" rating on the stock in a report on Wednesday, April 29th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Wednesday. Finally, Sanford C. Bernstein increased their price objective on Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $104.42.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $96.54 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The firm has a market cap of $18.41 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 3.07 and a beta of 0.45. The business has a 50 day moving average price of $90.17 and a 200-day moving average price of $90.15.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the previous year, the firm earned $2.07 earnings per share. The firm's revenue for the quarter was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts predict that Zimmer Biomet will post 8.53 earnings per share for the current year.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares of the company's stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.28% of the company's stock.

Institutional Trading of Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Main Management ETF Advisors LLC increased its stake in Zimmer Biomet by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider's stock valued at $986,000 after purchasing an additional 112 shares during the period. Citizens National Bank Trust Department boosted its stake in shares of Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider's stock worth $85,000 after buying an additional 141 shares during the period. LOM Asset Management Ltd grew its holdings in shares of Zimmer Biomet by 21.5% during the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider's stock worth $75,000 after buying an additional 147 shares during the last quarter. Oppenheimer & Co. Inc. grew its holdings in shares of Zimmer Biomet by 0.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider's stock worth $1,831,000 after buying an additional 152 shares during the last quarter. Finally, TD Private Client Wealth LLC increased its position in Zimmer Biomet by 15.3% in the 4th quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider's stock valued at $104,000 after acquiring an additional 153 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source